Clinical TrialJul 20, 2026, 08:02 AM
Eikon Therapeutics Abstracts Accepted for ESMO 2026 Congress
AI Summary
Eikon Therapeutics, Inc. announced the acceptance of seven abstracts for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. The presentations will cover updates across the company's clinical pipeline, including data from trials for EIK1001, EIK1003, EIK1004, and EIK1005. These updates include new data for EIK1001 in NSCLC, updated and initial data for EIK1003 in solid tumors and metastatic prostate cancer, initial results for EIK1004 in solid malignancies, and initial safety data for EIK1005.
Key Highlights
- Seven abstracts accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress.
- Updated data from TeLuRide-005, a Phase 2 trial of EIK1001 in stage 4 non-small cell lung cancer (NSCLC).
- Updated cohort data from Phase 1/2 study of EIK1003 in advanced solid tumors.
- Initial data from Phase 1/2 study of EIK1003 with abiraterone in metastatic prostate cancer.
- Initial results from Phase 1/2 study of EIK1004 in advanced solid malignancies.
- Initial safety, tolerability, and pharmacokinetics data for EIK1005, a Werner helicase inhibitor.
Price Impact
More from EIKN